Terrencem Kungel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

An expert panel recommended restricting the expanded first-line indication to patients whose metastatic castration-resistant prostate tumors have BRCA mutations.

Jorgej nievaTerrencem kungelLos angelesRavia madanSusan galbraithCancer researchNational cancer instituteDrug administrationOncologic drugs advisory committeeUniversity of southern californiaSouthern californiaProstate carcinomaAlignant prostate neoplasmProstate cancerAncer prostateBreast cancer